

AMENDMENTS TO THE CLAIMS

Please enter the following amendments to the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

1-39. **(Cancelled)**

40. **(Currently Amended)** A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group ~~comprising~~consisting of psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous carcinoma in situ, cancers and pre-malignant conditions, ichthyoses, hyperkeratosis and disorders of ~~keratinisation~~keratinization; consisting of administering to a patient in need of treatment for a hyperproliferative disease of the skin a pharmaceutical composition ~~to a patient in need thereof~~, wherein the pharmaceutical composition consists of a single inhibitor of the retinoic acid biosynthetic pathway, which is carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

41. **(Currently Amended)** A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group ~~comprising~~consisting of psoriasis, acne vulgaris, and hyperkeratosis; consisting essentially of administering to a patient in need of treatment for a hyperproliferative disease of the skin a pharmaceutical composition ~~to a patient in need thereof~~, wherein the pharmaceutical composition consists of a single inhibitor of the retinoic acid biosynthetic pathway, which is carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

42. **(Currently Amended)** A method of treating psoriasis consisting essentially of administering to a patient in need of treatment for psoriasis a pharmaceutical composition ~~to a patient in need thereof~~, wherein the pharmaceutical composition consists of a single inhibitor of the retinoic acid biosynthetic pathway, which is carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

43. **(Currently Amended)** The method of claim 40, wherein the disorder of ~~keratinisation~~keratinization is Darier's disease.

44. **(Currently Amended)** A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group ~~comprising~~consisting of psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous carcinoma in situ, cancers and pre-malignant conditions, ichthyoses, hyperkeratosis and disorders of ~~keratinisation~~keratinization; by topically administering to an affected area of the skin that is to be treated of a patient in need ~~thereof~~of treatment for a hyperproliferative disease of the skin, a pharmaceutical composition consisting of a single inhibitor of the retinoic acid biosynthetic pathway, which is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

45. **(Currently Amended)** A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group ~~comprising~~consisting of psoriasis, acne vulgaris, and hyperkeratosis; by topically administering to an affected area of the skin that is to be treated of a patient in need ~~thereof~~of treatment for a hyperproliferative disease of the skin, a pharmaceutical composition consisting of a single inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

46. **(Currently Amended)** A method of treating psoriasis by topically administering to an affected area of the skin that is to be treated of a patient in need ~~thereof~~of treatment for psoriasis, a pharmaceutical composition consisting of a single inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

47. **(Currently Amended)** The method of claim 44, wherein the disorder of ~~keratinisation~~keratinization is Darier's disease.

48. **(Currently Amended)** A method of treating a disease selected from psoriasis, acne vulgaris, actinic keratosis, solar keratosis, squamous carcinoma in situ, cancers and pre-malignant conditions, ichthyoses, hyperkeratosis and disorders of keratinization, consisting of administering to a patient in need of treatment for psoriasis a pharmaceutical composition ~~to a patient in need thereof~~, wherein the pharmaceutical composition consists of carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

49. **(Currently Amended)** A method of treating ~~a disease selected from~~ psoriasis, acne vulgaris ~~and~~or hyperkeratosis, ~~comprising~~consisting of administering to a patient in need of

treatment for psoriasis, acne vulgaris or hyperkeratosis, a pharmaceutical composition to a
~~patient in need thereof~~, wherein the pharmaceutical composition consists of carbenoxolone and
one or more pharmaceutically acceptable carriers, diluents or excipients.

50. **(Currently Amended)** A method of treating psoriasis consisting of administering
to a patient in need of treatment for psoriasis a pharmaceutical composition to a patient in need
~~thereof~~, wherein the pharmaceutical composition consists of carbenoxolone and one or more
pharmaceutically acceptable carriers, diluents or excipients.

51. **(Previously Presented)** The method of claim 48 wherein the disorder of
keratinization is Darier's disease.